Don't disagree and the CEO did make quite clear in the ********* interview that they are setting up institutional presentations for post school holidays - which would seem a strange comment to overseas investors, not understanding the holiday tendencies of George and Collins Street all skiiing in Aspen again at last.
WIth a big name US Pharma deal now on board and the company, where it can with confidentiality agreements in place on pricing with BioHorizons, indicating when it sees positive cash flows (the eternal holy grail of Insto's) you can be confident Insto's will get on board.
Its still just a case of Ortho-who, regards the share price alas? (to plagiarize someone else very adept description) Hopefully this will change with a bit of broker coverage this quarter or next.
(again the reference to the confidentiality agreements and lack of revenue/pricing detail comments in the recent interviews, is likely Paul acknowledging investor queries to his credit - investor communication is much improved)
OCC Price at posting:
39.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)